Financial Accountant Cantanhede

Financial Accountant
Cantanhede
Cantanhede, Coimbra, Portugal

Immunethep S. A. is seeking a Financial Accountant to join its team in Porto or Cantanhede, including remote work. The Financial Accountant will provide accurate financial information, ensuring all financial transactions are properly recorded, assist in budgeting and forecasting and
- funded projects. The Financial Accountant will support the Finance Director both managerially and operationally.

Minimum Qualifications:

-A bachelor’s degree in accounting, finance, economics or a related field;

-3+ years of experience in accounting or finance;

-Strong understanding of accounting principles, practices and procedures;

-Integrity, credibility and maturity for confidential issues;

-Excellent time management skills and ability to prioritize work in a
- paced environment;

-Critical thinking and ability to show initiative;

-Ability to work well in a team and independently.

Preferred Qualifications:

-Experienced in bookkeeping;

-Robust Excel skills, with ability to create pivot tables, develop graphs and charts, and utilize formulas;

-Strong communications skills, written and oral (in English);

-Exceptional analytical and quantitative skills.

To apply for this position, please send your CV and a Motivation Letter to careers@immunethep.com before 31st of August 2025, indicating the reference IMTP15/2025 in the
- mail Subject. There will be a short list of selected candidates that will be invited for an interview. We will notify by
- mail all candidates of our decision.

Immunethep is a Biotech company (spin-off from the University of Porto), located in Cantanhede (Portugal), developing
- bacterial immunotherapies with a novel mechanism of action based on the discovery of a virulence mechanism shared by various bacteria that cause
- threatening infections. Immunethep received two prestigious grants from CARB-X for the development of an
- bacterial vaccine targeting invasive E. coli infections and from PACE to develop novel monoclonal antibodies targeting infections caused by E. coli and Klebsiella pneumoniae.

For more information visit our webpage at www.immunethep.com.